REGENXBIO (RGNX) Stock Forecast & Price Target

Regenxbio is positioned favorably because its lead RGX-202 program has a clearly defined accelerated-approval path, with a rolling BLA starting in 3Q26, completion in 1Q27, and potential approval in 2H27 supported by safety data from more than 60 patients plus pivotal efficacy data. The thesis is strengthened by RGX-202’s differentiated profile: it met the primary endpoint with >93% microdystrophin expression at Week 12, showed clear functional improvement, and was described as the only DMD gene therapy in development with such evidence, while RGX-121 also has FDA alignment for resubmission without additional patients or studies. Financially, 2Q26 revenue reached $108.0M, net income was $22.7M, and pro forma cash rose to about $313M, extending runway into 4Q27 and reducing near-term execution risk.

Regenxbio is facing a material setback because the FDA placed a clinical hold on RGX-121 after asymptomatic spine MRI findings were detected in five CAMPSIITE participants, forcing the company to pause its BLA resubmission and extend follow-up. Although the findings were deemed nonserious and the patients remain clinically stable, the causation and prevalence of these abnormalities are unknown, which raises uncertainty around the benefit-risk profile of a program dosed three to six years ago. This is particularly problematic for a clinical-stage biotech with no approved products, since one high-profile safety question can erode confidence in the broader gene therapy platform and delay value realization across the pipeline.